Prognostic and predictive value of HURP in non‑small cell lung cancer

Wang, Qi; Chen, Yaokun; Feng, Hui; Zhang, Biyuan; Wang, Haiji

doi:10.3892/or.2018.6280

Cited by 27 publications

(32 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DLGAP5, a microtubule-associated protein, is phosphorylated by Aurora kinase A (AURKA) (43). In addition, DLGAP5 upregulation is associated with poor prognosis of patients with colorectal cancer (44), lung cancer (10), bladder cancer (11) and prostate cancer (12), indicating that DLGAP5 plays an important role in cancer prognosis. Branchi et al (44) reported that DLGAP5 was associated with the nodal status, and high DLGAP5 expression levels were associated with a less favorable overall survival rate in distinct molecular colorectal cancer subtypes.…”

Section: Discussionmentioning

confidence: 99%

“…The human discs large-associated protein 5 (DLGAP5) gene, which is mapped to chromosome 14q22.3, is a cell cycle regulator involved in carcinogenesis (9). Wang et al (10) reported that DLGAP5 was upregulated in non-small cell lung cancer (NSCLC) and was associated with a shorter survival time. In cytological experiments, the knockdown of DLGAP5 caused inhibition of proliferation, migration and invasion of NSCLC cells (10).…”

Section: Introductionmentioning

confidence: 99%

“…Wang et al (10) reported that DLGAP5 was upregulated in non-small cell lung cancer (NSCLC) and was associated with a shorter survival time. In cytological experiments, the knockdown of DLGAP5 caused inhibition of proliferation, migration and invasion of NSCLC cells (10). Previous studies have also shown that the expression levels of DLGAP5 are upregulated in bladder (11), prostate (12) and liver cancer (13), as well as leukemia (14) were associated with poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Elevated mRNA expression levels of DLGAP5 are associated with poor prognosis in breast cancer

Dong

Zhang

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Breast cancer is the most commonly diagnosed type of cancer and one of the leading causes of cancer-associated mortality in women. In addition, the underlying molecular mechanisms of the occurrence and development of breast cancer requires further investigation. In the present study, bioinformatics analysis was performed to identify differentially expressed genes (DEGs) between breast cancer and normal breast tissues to investigate the underlying molecular mechanisms. In addition, reverse transcription-quantitative PCR and immunohistochemistry (IHC) were performed to investigate the protein and mRNA expression levels of a specific DEG, discs large-associated protein 5 (DLGAP5). A Cell Counting Kit-8 assay and flow cytometry analysis were used to assess the effects of DLGAP5 on cell proliferation. In total, 85 DEGs were identified in the three Gene Expression Omnibus datasets, including 40 upregulated and 45 downregulated genes. In addition, 30 hub genes were identified following the construction of a protein-protein interaction network, and 28 of the 30 hub genes were established to be indicators of breast cancer prognosis. DLGAP5 was highly expressed in breast cancer specimens, and its expression levels were correlated with clinical stage and lymph node status. In addition, downregulation of DLGAP5 repressed the proliferation of breast cancer MDA-MB-231 cells and induced cell cycle arrest. Additionally, DLGAP5 was identified to be localized in the mitochondria, and the presence of a conserved microtubule-associated proteins 1A/1B light chain 3B-interacting region motif suggested that DLGAP5 may serve a role in mitophagy. The present results demonstrated an association between DLGAP5 expression levels and the clinicopathological characteristics of patients with breast cancer using IHC. In conclusion, DLGAP5 may be a promising target in the diagnosis and treatment of breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Elevated mRNA expression levels of DLGAP5 are associated with poor prognosis in breast cancer

Dong

Zhang

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…What is more, its high level of expression had a negative impact on the progression-free survival (HR=2.71) as well as on the overall survival (HR=1.75) in NSCLC. High levels of HURP expression in the IHC studies also correlated with a higher clinical stage and grade (43).…”

Section: Revision Of Novel Prognostic Factors In Lung Cancermentioning

confidence: 71%

Novel prognostic molecular markers in lung cancer (Review)

2020

View full text Add to dashboard Cite

Lung carcinoma, especially in its most commonly diagnosed non-small cell histological form, is a challenge to diagnose and treat worldwide, due to the prognosis in patients with this type of cancer being poor and mortality rates being high. However, a number of patients with this type of lung carcinoma exhibit a longer than average overall survival. The specific molecular background of non-small-cell lung cancer that favors longer survival has not yet been determined. The aim of the current study was to review articles published in the years 2017-2018 and create a list of the most important and strongest non-conventional factors that could be used in the future assessment of the prognosis of patients with adenocarcinoma and squamous cell carcinoma of the lung who cannot undergo current targeted therapy. Analysis identified multiple prognostic factors in non-small cell lung carcinoma, including tumor mutational burden, which was revealed to be independent of the tumor stage or grade as well as other factors, including age, sex or targeted therapy effects. The selected molecular factors exhibit the potential to be used in the treatment of patients with specific problematic lung cancer, and may contribute to setting recommendations for the diagnosis, prognosis and treatment of individual patients with lung cancer.

show abstract

“…The combination of paclitaxel and platinum drugs is a recognized first-line chemotherapy regimen for the treatment of advanced NSCLC. 6 However, the NCCN Clinical Practice Guidelines in Oncology for NSCLC recommend conventional treatment options without clarifying the specific details, such as the times of administration, cycles of chemotherapy, and doses of paclitaxel in combination with platinum drugs, and thus may cause great differences between different paclitaxelplatinum regimens in clinical practice. Of particular concern is that the efficacy and safety of a paclitaxel-platinum regimen may not be identical in different populations.…”

Section: Introductionmentioning

confidence: 99%

Racial Disparities in Survival Among Advanced Non-Small Cell Lung Cancer Patients First-Treated with The Combination of Paclitaxel and Platinum

Zhao

Wang

Huang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: In clinical practice, different chemotherapy schedules for NSCLC have potential impacts on overall survival, but not specific in NCCN guidelines. Although some meta-analyses have been conducted to identify the influencing factors, the results are limited by method. Our study is helpful to supplement the NCCN Guidelines.Methods: In order to evaluate and quantify the potential relationship between demographic characteristics, disease characteristics, etc. and overall survival as well as their impact on objective response rate and safety, we developed parametric proportional hazard regression models to describe the overall survival of advanced NSCLC patients first-treated with the paclitaxel-platinum regimen. Results: The principal finding of this research was that race significantly affected hazard of dying. Hazard of dying was 1.4 times higher in non-East Asians than in East Asians, and the hazard ratio of the OS curve was 0.71(95%CI: 0.65-0.78). The median survival time in East Asians and non-East Asians were estimated as 12.2 (95%CI: 10.5, 14.4) and 8.4 (95%CI: 6.5. 11.0) months, respectively. The ORR was 37% (95%CI: 32, 41) and 28% (95%CI: 25, 32) in East Asians and non-East Asians, respectively. Conclusions: Paclitaxel-platinum regimen had different efficacy in two racial groups. The developed model suggests that the efficacy and safety of paclitaxel-platinum regimen can vary between different racial populations because of differences in influencing factors (doses, platinum type, cycles, etc.)

show abstract

Prognostic and predictive value of HURP in non‑small cell lung cancer

Cited by 27 publications

References 26 publications

Elevated mRNA expression levels of DLGAP5 are associated with poor prognosis in breast cancer

Elevated mRNA expression levels of DLGAP5 are associated with poor prognosis in breast cancer

Novel prognostic molecular markers in lung cancer (Review)

Racial Disparities in Survival Among Advanced Non-Small Cell Lung Cancer Patients First-Treated with The Combination of Paclitaxel and Platinum

Contact Info

Product

Resources

About